Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306355 | 0.96 | GPR35 (0.46) | GPR35MAPK1ALDH1A1HPGDTP53 | |
| SCHEMBL29847105 | 0.96 | GPR35 (0.46) | GPR35MAPK1ALDH1A1HPGDTP53 | |
| SCHEMBL6999559 | 0.94 | GPR35 (0.44) | GPR35MAPK1ALDH1A1HPGDTP53 | |
| SCHEMBL6997080 | 0.94 | GPR35 (0.44) | GPR35MAPK1ALDH1A1HPGDTP53 | |
| SCHEMBL9452619 | 0.81 | MAPT (0.41) | GPR35MAPK1ALDH1A1HPGDTP53 | |
| SCHEMBL14411992 | 0.80 | SIRT6 (0.43) | GPR35MAPK1ALDH1A1HPGDTP53 | |
| SCHEMBL24869958 | 0.79 | PNMT (0.54) | GPR35MAPK1ALDH1A1HPGDTP53 | |
| SCHEMBL28069542 | 0.79 | PNMT (0.54) | GPR35MAPK1ALDH1A1HPGDTP53 | |
| SCHEMBL6197256 | 0.79 | MAPT (0.41) | GPR35MAPK1ALDH1A1HPGDTP53 | |
| SCHEMBL28027769 | 0.78 | GPR35 (0.44) | GPR35MAPK1ALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597088-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-11-01 | — | — | EP | disclosed |
| CN-103080094-B | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO | 2015-06-24 | — | — | CN | disclosed |
| US-8962613-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| CN-103910718-A | Bicyclic-substituted pyrazolone azo compounds, and preparation method and use thereof | QILU PHARMACEUTICAL CO LTD | 2014-07-09 | — | — | CN | disclosed |
| US-20130172550-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
| EP-2597088-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2013-05-29 | — | — | EP | disclosed |
| CN-103080094-A | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO | 2013-05-01 | — | — | CN | disclosed |
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| CN-102060732-A | 5-amino-4-hydroxy-N-aryl azelamide derivatives as well as preparation methods and medical applications thereof | JIANGSU HENGRUI MEDICINE CO | 2011-05-18 | — | — | CN | disclosed |
| EP-2305641-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-04-06 | — | — | EP | disclosed |
| CN-1136203-C | Benzoxazine and benzothiazine derivatives and their use in medicine | ���ֹɷݹ�˾ | 2004-01-28 | — | — | CN | disclosed |
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| CN-1278802-A | Benzoxazine and Benzothiazine derivatives and their use in pharmaceuticals | SCHERING AG (DE) | 2001-01-03 | — | — | CN | disclosed |
| EP-1015437-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012915-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-18 | — | — | WO | disclosed |
| US-5442060-A | Treating hyperlipemia, atherosclerosis | MITSUBISHI KASEI CORPORATION (JP) | 1995-08-15 | — | — | US | disclosed |
| EP-0591830-A1 | Carboxamide and urea derivatives having ACAT-inhibiting activityM | Mitsubishi Chemical Corporation (JP) | 1994-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172550-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX4, P2RX3, P2RX7 | GPR35 318/4885MAPK1 734/4885ALDH1A1 2732/4885 |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | PTGER1, PTGER2, GPER1 | GPR35 97/4885MAPK1 728/4885ALDH1A1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.